A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
MTAP-deleted NSCLC
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
3 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 61 (final count)
- Started
- Dec 26, 2024
- Main results expected
- Oct 31, 2026
- Fully finished
- Nov 30, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response (OR) per RECIST 1.1
Measured over: Up to 35 months
Objective response (OR) Measured by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) and Assessed per Response Evaluation Criteria in Solid Tumors v1.1 (RECIST 1.1)
Measured over: Up to 35 months
Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
Measured over: Up to 35 months
Number of Participants Experiencing Events of Interest (EOIs)
Measured over: Up to 35 months
Maximum Concentration (Cmax) of anvumetostat
Measured over: Cycle 1: Day 1 and Day 15 pre-dose, 0.5 hours, 1 hour, 2 hours, 4 hours, and 6 hours post-dose; Cycle 2: Day 1 and Day 15 pre-dose; Cycles 3-5: Day 1 pre-dose
Time to Cmax (Tmax) of anvumetostat
Measured over: Cycle 1: Day 1 and Day 15 pre-dose, 0.5 hours, 1 hour, 2 hours, 4 hours, and 6 hours post-dose; Cycle 2: Day 1 and Day 15 pre-dose; Cycles 3-5: Day 1 pre-dose
Area Under The Concentration-time Curve (AUC) of anvumetostat
Measured over: Cycle 1: Day 1 and Day 15 pre-dose, 0.5 hours, 1 hour, 2 hours, 4 hours, and 6 hours post-dose; Cycle 2: Day 1 and Day 15 pre-dose; Cycles 3-5: Day 1 pre-dose
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06593522 · record last updated 2026-05-28 · checked 2026-11-09 15:47 UTC